Search Results - "CUTLER, D. L"

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects by Cutler, D. L., Tendolkar, A., Grachev, I. D.

“…Summary What is known and Objective:  Preladenant (SCH420814, MK‐3814) is a highly selective orally bioavailable non‐methylxanthine adenosine 2A (A2A) receptor…”
Get full text

Preladenant, a selective adenosine A2A receptor antagonist, is not associated with QT/QTc prolongation by Wang, Z., Xuan, F., Lin, W. H., Troyer, M. D., Tendolkar, A., Cutler, D. L.

“…Purpose Preladenant is an orally administered adenosine 2A (A 2A ) receptor antagonist in phase III development for Parkinson’s disease treatment. This…”
Get full text

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus by Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. L.

“…Ertugliflozin is a highly selective and potent inhibitor of the sodium‐glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus…”
Get full text

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours by Awada, A., Eskens, F.A.L.M., Piccart, M., Cutler, D.L., van der Gaast, A., Bleiberg, H., Wanders, J., Faber, M.N., Statkevich, P., Fumoleau, P., Verweij, J.

“…A single-agent dose-escalating phase I study on the farnesyl transferase inhibitor SCH 66336 was performed to determine the safety profile and recommended dose…”
Get full text

Phase I and Pharmacokinetic Study of the Oral Farnesyl Transferase Inhibitor SCH 66336 Given Twice Daily to Patients With Advanced Solid Tumors by ESKENS, Ferry A. L. M, AWADA, Ahmad, PICCART, Martine, CUTLER, David L, DE JONGE, Maja J. A, LUYTEN, Gré P. M, FABER, Marije N, STATKEVICH, Paul, SPARREBOOM, Alex, VERWEIJ, Jaap, HANAUSKE, Axel-R

“…A single-agent dose-escalating phase I and pharmacokinetic study on the farnesyl transferase inhibitor SCH 66336 was performed to determine the safety profile,…”
Get full text

Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration by Pajkrt, D, Camoglio, L, Tiel-van Buul, MC, de Bruin, K, Cutler, DL, Affrime, MB, Rikken, G, van der Poll, T, ten Cate, JW, van Deventer, SJ

“…To determine the effects of IL-10 on cytokine and granulocyte responses during endotoxemia, two groups of eight healthy male volunteers were challenged with…”
Get full text

In vivo effects of interleukin-10 on human cytochrome P450 activity by Gorski, J. Christopher, Hall, Stephen D., Becker, Paula, Affrime, Melton B., Cutler, David L., Haehner‐Daniels, Barbara

“…Background Injection of lipopolysaccharide into human volunteers leads to an increase in serum interleukin‐1β, interleukin‐6, and tumor necrosis factor‐α and a…”
Get full text

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients by Dai, M.-S., Chao, T.-Y., Chao, T.-C., Chiu, C.-F., Lu, Y.-S., Shiah, H.-S., Wu, Y.-Y., Gerald Fetterly, G., Hung, N., Cutler, D.L., Kwan, R., Douglas Kramer, D., Chan, W.-K., Hung, T.

Get full text

Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers by Huhn, Richard D., Radwanski, Elaine, Gallo, Jose, Affrime, Melton B., Sabo, Ron, Gonyo, Gerilyn, Monge, April, Cutler, David L.

“…Interleukin‐10 inhibits T‐lymphocyte activation and proliferation and lipopolysaccharide‐induced monocyte production of proinflammatory cytokines. Fifty‐four…”
Get full text

Pharmacokinetics and Immunomodulatory Properties of Intravenously Administered Recombinant Human Interleukin-10 in Healthy Volunteers by Huhn, Richard D., Radwanski, Elaine, O'Connell, Sean M., Sturgill, Marc G., Clarke, Laura, Cody, Ronald P., Affrime, Melton B., Cutler, David L.

“…Normal volunteers received single doses of recombinant human interleukin-10 (rhIL-10; n = 6 per group) or placebo (n = 3 per group) by intravenous injection to…”
Get full text

Population pharmacokinetics of temozolomide in cancer patients by JEN, J. Frank, CUTLER, David L, PAI, Sudhakar M, BATRA, Vijay K, AFFRIME, Melton B, ZAMBAS, Demetris N, HEFT, Samuel, HAJIAN, Gerald

“…To evaluate covariate effects on the pharmacokinetics of temozolomide in cancer patients, and to explore the dose-pharmacokinetics-toxicity relationship of…”
Get full text

Pharmacokinetics and leukocyte responses of recombinant human interleukin-10 by RADWANSKI, E, CHAKRABORTY, A, VAN WART, S, HUHN, R. D, CUTLER, D. L, AFFRIME, M. B, JUSKO, W. J

“…To study the pharmacokinetics and ex vivo leukocyte responses of recombinant human IL-10 (rHuIL-10) following single s.c. and i.v. dosing. A randomized two-way…”
Get full text

Pharmacokinetic and Adrenal Interactions of IL-10 and Prednisone in Healthy Volunteers by Chakraborty, Abhijit, Blum, Robert A., Mis, Suzette M., Cutler, David L., Jusko, William J.

“…The pharmacokinetic and adrenal interactions of recombinant human interleukin‐10 and prednisolone were examined in this open‐label, randomized, four‐way…”
Get full text

Disposition of Recombinant Human Interleukin-10 in Subjects with Various Degrees of Renal Function by Andersen, Scott R., Lambrecht, Lawrence J., Swan, Suzanne K., Cutler, David L., Radwanski, Elaine, Affrime, Melton B., Garaud, Jean-Jacques

“…The pharmacokinetics of intravenously administered recombinant human interleukin‐10 (rHuIL‐10) were evaluated in 18 subjects with creatinine clearances (Clcr)…”
Get full text

Pharmacokinetics of flutamide in patients with renal insufficiency by ANJUM, S, SWAN, S. K, LAMBRECHT, L. J, RADWANSKI, E, CUTLER, D. L, AFFRIME, M. B, HALSTENSON, C. E

“…Aims The aim of this study was to determine the pharmacokinetic parameters of flutamide, a nonsteroidal antiandrogenic compound, and its pharmacologically…”
Get full text

Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers by Chakraborty, Abhijit, Blum, Robert A., Cutler, David L., Jusko, William J.

“…Objective The pharmacoimmunodynamic interactions of recombinant human interleukin‐10 and prednisolone were examined in 12 normal male volunteers. Methods…”
Get full text

Clinical, hematologic, and immunologic effects of interleukin-10 in humans by FUCHS, A. C, GRANOWITZ, E. V, CUTLER, D. L, GRINT, P. C, DINARELLO, C. A, SHAPIRO, L, VANNIER, E, LONNEMANN, G, ANGEL, J. B, KENNEDY, J. S, RABSON, A. R, RADWANSKI, E, AFFRIME, M. B

“…We conducted a double-blind, placebo-controlled study to investigate the safety, pharmacokinetics, and immunological properties of interleukin-10 (IL-10)…”
Get full text

Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide by BEALE, P, JUDSON, I, MOORE, S, STATKEVICH, P, MARCO, A, CUTLER, D. L, REIDENBERG, P, BRADA, M

“…Temozolomide is an imidazotetrazine alkylating agent which undergoes chemical conversion at physiological pH to the active species…”
Get full text

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity by Adjei, A A, Erlichman, C, Davis, J N, Cutler, D L, Sloan, J A, Marks, R S, Hanson, L J, Svingen, P A, Atherton, P, Bishop, W R, Kirschmeier, P, Kaufmann, S H

“…Farnesyl protein transferase (FT), an enzyme that catalyzes the first step in the posttranslational modification of ras and a number of other polypeptides, has…”
Get full text

Insulin-resistant diabetes mellitus and hypermetabolism in mandibuloacral dysplasia: a newly recognized form of partial lipodystrophy by Cutler, D L, Kaufmann, S, Freidenberg, G R

“…Mandibuloacral dysplasia (MAD) is a syndrome characterized by partial lipodystrophy and a distinct phenotype, which includes progressive osteolysis of the…”
Get more information